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Abstract
Background: The aim of the study was to compare 7 available risk models in the prediction of 
30-day mortality following transcatheter aortic valve implantation (TAVI). Heart team decision 
supported by different risk score calculations is advisable to estimate the individual procedural 
risk before TAVI.
Methods: One hundred and fifty-six consecutive patients (n = 156, 48% female, mean age 
80.03 ± 8.18 years) who underwent TAVI between March 2010 and October 2014 were in-
cluded in the study. Thirty-day follow-up was performed and available in each patient. Base-
line risk was calculated according to EuroSCORE I, EuroSCORE II, STS, ACEF, Ambler’s, 
OBSERVANT and SURTAVI scores.
Results: In receiver operating characteristics analysis, neither of the investigated scales was 
able to distinguish between patients with or without an endpoint with areas under the curve 
(AUC) not exceeding 0.6, as follows: EuroSCORE I, AUC 0.55; 95% confidence intervals (CI) 
0.47–0.63, p = 0.59; EuroSCORE II, AUC 0.59; 95% CI 0.51–0.67, p = 0.23; STS, AUC 0.55; 
95% CI 0.47–0.63, p = 0.52; ACEF, AUC 0.54; 95% CI 0.46–0.62, p = 0.69; Ambler’s, AUC 
0.54; 95% CI 0.46–0.62, p = 0.70; OBSERVANT, AUC 0.597; 95% CI 0.52–0.67, p = 0.21;  
SURTAVI, AUC 0.535; 95% CI 0.45–0.62, p = 0.65. SURTAVI model was calibrated best in  
high-risk patients showing coherence between expected and observed mortality (10.8% vs. 9.4%, 
p = 0.982). ACEF demonstrated best classification accuracy (17.5% vs. 6.9%, p = 0.053,  
observed mortality in high vs. non-high-risk cohort, respectively).
Conclusions: None of the investigated risk scales proved to be optimal in predicting 30-day 
mortality in unselected, real-life population with aortic stenosis referred to TAVI. This data 
supports primary role of heart team in decision process of selecting patients for TAVI. (Cardiol J  
2016; 23, 2: 169–177)
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Introduction
Transcatheter aortic valve implantation (TAVI) 
is a procedure designed for inoperable or high-risk 
patients with severe aortic stenosis (AS). Accord-
ing to European guidelines, the heart team should 
make the decision whether a patient is not suitable 
for conventional surgical replacement (aortic valve 
replacement) and therefore should undergo TAVI 
[1]. Two risk scores have been suggested as a pos-
sible aid to heart team’s decision — logistic Euro-
pean System for Cardiac Operative Risk Evaluation 
(EuroSCORE) > 20% and The Society of Thoracic 
Surgeons’s (STS) score > 10%. Both risk scores 
have been developed and validated in surgical set-
tings and are believed to either overestimate or un-
derestimate mortality, respectively [2–4]. Recently, 
a number of new risk scores or models have been 
developed, some of them based on surgical patients 
(EuroSCORE II, age-creatinine-ejection fraction 
[ACEF], Ambler’s risk score) [5–7], other on those 
undergoing TAVI (OBSERVANT, SURTAVI model) 
[8, 9]. There is few data comparing performance 
of multiple risk stratification models in unselected 
population of TAVI patients. Therefore, the aim of 
this study was to compare seven available risk mod-
els — logistic EuroSCORE, EuroSCORE II, STS, 
ACEF, Ambler’s, OBSERVANT and SURTAVI — in 
the prediction of 30-day mortality following TAVI.
Methods
Study design and population
From March 2010 to October 2014, 156 con-
secutive, inoperable or high-risk patients (n = 156, 
48% female, mean age of 80.03 ± 8.18 years) 
with severe symptomatic AS (aortic valve area 
< 1.0 cm2, or indexed valve area less than 
0.6 cm2/m2, or mean gradient > 40 mm Hg, or 
maximum jet velocity > 4.0 m/s, or velocity ratio 
< 0.25), after heart team decision treated with 
TAVI, were prospectively enrolled. Both, balloon- 
(Edwards Sapien®) and self-expandable (Core-
Valve®, Medtronic) aortic valve prostheses were 
used and all standard delivery routes were applied. 
It was an all-comers study and no exclusion criteria 
were used. Informed consent was obtained from all 
participating patients and local Ethics Committee 
granted permission for the study.
Predicted mortality was calculated according 
to logistic EuroSCORE [2], EuroSCORE II [5], STS 
[3], Ambler’s [6], ACEF [7] and OBSERVANT [9] 
scores. In case of SURTAVI [8] model, patients 
were categorized straightaway into three groups 
— low, intermediate and high risk — due to lack 
of proper formula or calculator enabling continu-
ous risk calculation. In the remaining 6 risk scores 
— patients were subdivided into tertiles of low, 
intermediate or high risk, based on their predicted 
mortality in each scale. Afterwards, for each scale 
predicted and observed mortality of patients from 
high-risk group were compared to predicted and 
observed mortality of non-high-risk group (pooled 
low- and intermediate-risk groups).
Risk scores characteristics
In the present study, besides established and 
recognized scales predicting 30-day mortality, used 
in Europe and North America, namely logistic Euro - 
SCORE and STS score, newer and less validated 
models were implemented.
Logistic EuroSCORE [2] takes into considera-
tion the same 17 risk factors as its predecessor 
— additive EuroSCORE [10] — a risk model that 
was designed to predict early mortality after major 
cardiac surgery — with additional logistic regres-
sion analysis aiming to provide more accurate risk 
predictions in high-risk patients. Original model 
was developed and validated in 1999 on a dataset 
of more than 13,000 patients.
EuroSCORE II [5], based upon data from 
22,000 patients and characterized by better calibra-
tion and similar discrimination power in predict-
ing early mortality after cardiac surgery, replaced 
original EuroSCORE in 2011. It includes 18 factors.
The 2008 STS’ risk model [3] was conceived 
in order to assess early postoperative course after 
coronary artery bypass grafting (CABG), valve sur-
gery or both. It is by far the most complex model 
taking into consideration 39 factors, developed 
and validated based upon data from almost 975,000 
patients and providing estimations on early mortal-
ity as well as early complications including stroke, 
renal failure or prolonged ventilation.
Ambler’s score is a risk model created in order to 
assess early mortality after aortic and/or mitral valve 
surgery with or without concomitant CABG. It was de-
veloped and validated in 2005 [6] based upon a dataset 
from almost 33,000 patients and consists of 14 factors.
ACEF was also designed as an early postop-
erative mortality estimation tool. Its  authors have 
made an effort to substantially limit the number of 
included factors — to only 3 — in order to facilitate 
its clinical application. Published in 2009 [7], devel-
oped and validated on almost 9,000 patients, it has 
proven to offer similar accuracy and calibration as 
established risk models when applied to patients 
undergoing elective cardiac surgery.
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SURTAVI model is a 10-factor risk stratifica-
tion system proposed in 2012 in order to estimate 
early mortality in patients undergoing TAVI as part 
of “SURgical replacement and Transcatheter Aortic 
Valve Implantation” (SURTAVI) trial [8].
OBSERVANT is also a risk model designed 
specifically for TAVI procedures. Published in 2014, 
developed and validated based upon data from 1,900 
TAVI patients, it takes into consideration 7 factors. 
In the original study [9], it managed to offer better 
calibration and accuracy than logistic EuroSCORE 
with equally good discrimination.
Detailed list of elements constituting the glob-
al risk in respective scales is presented in Table 1.
Data collection and endpoints
Based on pre-procedural evaluation charts, 
predicted mortality was calculated for respective 
models. Thirty days after the procedure each living 
patient was readmitted for scheduled echocardio-
graphic assessment. In case of death occurrence 
between discharge from index hospitalization and 
30-day scheduled admission, source documenta-
tion was obtained. Primary endpoint of the study 
was the assessment of discriminating abilities of 
respective risk models in terms of 30-day mortality. 
Secondary endpoints were the calibration of the 
scales in high-risk vs. non high-risk subpopulations 
and comparison of their classification accuracy.
Statistical analysis
Continuous variables, expressed as means 
± standard deviation, were compared using Student’s 
t-test. Categorical variables, expressed as counts 
and percentages, were compared using c2 test or 
Fisher’s exact test, as appropriate.
Receiver operating characteristic (ROC) anal-
ysis, producing an area under the curve (AUC) 
(c statistic) with 95% confidence intervals (CI), 
was used for discrimination of the predictive scores 
of 30-day mortality. Calibration (ability to match 
patients’ expected vs. observed mortality) was 
determined by binomial testing of expected vs. 
observed 30-day mortality. Classification accuracy 
was assessed by comparison of survival curves of 
high and non-high risk groups (log-rank test).
All probability values reported are 2-sided and 
a value < 0.05 was considered to be significant. All 
data were processed using the MedCalc Software, 
version 15.2.2 (MedCalc Software, Ostend, Belgium).
Results
Baseline characteristics
Detailed characteristics of the study popu-
lation are presented in Table 2. In total, 48.1% 
of patients were female (n = 75) and 23.7% 
were over 85 years old (n = 37). The minority 
of patients had left ventricular ejection fraction 
(LVEF) < 40% (n = 29, 18.6%) and 91 (58.3%) 
patients had admission glomerular filtration rate 
(GFR) lower than 60 mL/min/m2. Non-transfem-
oral access was used in 35 (22.4%) patients and 
self-expandable valve prosthesis were preferred 
(n = 98, 62.8%).
Mortality
Thirty-day follow-up was complete and 
available in all patients (100%). There were 
15 (9.6%) patients who died within 30 days 
after the procedure or later if the patient was 
not discharged after 30 days. Majority of deaths 
occurred within first 2 days after the procedure 
(n = 9, 5.8%) and were cardiac-related (Fig. 1). 
Univariate analysis of possible predictive fac-
tors of early mortality demonstrated no impact 
of age, gender, LVEF, type of prosthesis, chosen 
approach, nor pulmonary hypertension on early 
mortality (Table 2). However, mitral regurgita-
tion (MR) ≥ 3 diagnosed at baseline and chronic 
kidney disease (GFR < 30 mL/min/1.73 m2) oc-
curred significantly more frequently in patients 
who died (p = 0.036 and p = 0.04, respectively). 
Severe aortic regurgitation (AR) immediately 
after TAVI was also found more often in patients 
who died (20% vs. 4.3%, p = 0.04).
Discriminating abilities of risk models
In ROC analysis, neither of the investigated 
scales was able to distinguish between patients 
with or without an endpoint, with c-statistic not 
exceeding 0.6, as follows: logistic EuroSCORE I, 
AUC 0.55, 95% CI 0.47–0.63, p = 0.59; Euro-
SCORE II, AUC 0.59, 95% CI 0.51–0.67, p = 0.23; 
STS, AUC 0.55, 95% CI 0.47–0.63, p = 0.52; ACEF, 
AUC 0.54, 95% CI 0.46–0.62, p = 0.69; Ambler’s, 
AUC 0.54, 95% CI 0.46–0.62, p = 0.70; OBSER-
VANT, AUC 0.597, 95% CI 0.52–0.67, p = 0.21; 
SURTAVI, AUC 0.535, 95% CI 0.45–0.62, p = 0.65. 
Figure 2 demonstrates comparison of risk 
mo dels‘ ROC.
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Table 1. Presentation of risk factors in respective risk stratification models.
Euro-
SCORE I
Euro-
SCORE II
STS ACEF Ambler’s OBSERVANT SURTAVI
Patient characteristics
Age + + + + +
Sex + + + +
Height +
Weight +
Body mass index +
Ethnicity +
Co-morbid conditions
Diabetes + + + +
Hypertension + +
Chronic lung/pulmonary disease + + + +
Extracardiac arteriopathy + + +
Peripheral vascular disease + +
Neurological dysfunction + + +
Frailty +
Cerebrovascular accident +
Creatinine clearance + + +
Serum creatinine + + + +
Dialysis-dependent renal failure + +
Immunosuppressive therapy +
Poor mobility +
Cardiac history
NYHA classification + + +
Unstable angina + +
CCS class IV angina +
Recent myocardial infarction + + +
Arrhythmias + +
Previous cardiac surgery + + + +
Previous CABG +
Previous valvular disease +
Previous PCI +
Previous balloon aortic valvuloplasty +
Active endocarditis + + +
Number of diseased coronary vessels +
Type and severity of valvular disease +
Hemodynamic state
Pulmonary hypertension + + + +
Ejection fraction + + + + + + +
Critical preoperative state + + +
Cardiogenic shock +
Resuscitation +
Inotropic agents +
Intra-aortic balloon pump +
Procedure
Emergency + + +
Surgery on thoracic aorta + + +
Aortic valve surgery + + +
Mitral valve surgery + +
Aortic and mitral valve surgery + +
Tricuspid valve surgery +
Surgery for CHD +
Rhythmological surgery +
Concomitant CABG + +
Concomitant tricuspid valve surgery + +
Post-infarct septal rupture +
CABG — coronary artery by-pass grafting; CCS — Canadian Cardiovascular Society; CHD — congenital heart disease; NYHA — New York 
Heart Association; PCI — percutaneous coronary intervention; TAVI — transcatheter aortic valve implantation
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Calibration in high risk vs. non-high  
risk group
The SURTAVI risk model showed best calibration 
with no significant difference between the number of 
expected and observed deaths in high-risk patients 
(10.8% vs. 9.4%, p = 0.982), whereas EuroSCORE I 
achieved best calibration in the non-high risk cohort 
(9.6% vs. 8.6%, p = 0.984). Detailed comparison of 
high-risk patients group vs. non-high risk patients 
group in each scale is presented in Figure 3.
Table 2. Demographics, baseline and procedural characteristics.
Overall population  
(n = 156)
Patients who  
died (n = 15)
Patients who  
survived (n = 141)
P
Demographics
Female gender 75 (48.1%) 5 (33.3%) 70 (49.6%) 0.35
Age [years] 80.03 ± 8.18 77.75 ± 10.15 80.28 ± 7.95 0.26
Baseline characteristics
Body mass index [kg/m2] 27.07 ± 4.21 26.54 ± 1.22 27.13 ± 4.41 0.23
Hypertension 111 (71.2%) 11 (73.3%) 100 (70.9%) 0.92
Diabetes 58 (37.2%) 5 (33.3%) 53 (37.6%) 0.97
GFR < 30 mL/min 15 (9.6%) 4 (26.7%) 11 (7.8%) 0.04
Hemodialysis 7 (4.5%) 2 (13.3%) 5 (3.5%) 0.14
Previous PCI 58 (37.4%) 4 (26.7%) 54 (38.6%) 0.42
Previous CABG 15 (9.6%) 1 (6.7%) 14 (9.9%) 1
Recent myocardial infarction 17 (10.9%) 1 (6.7%) 16 (11.3%) 0.91
History of stroke/TIA 22 (14.1%) 1 (6.7%) 21 (14.9%) 0.63
Atrial fibrillation 56 (35.9%) 3 (20.0%) 53 (37.6%) 0.29
Chronic obstructive pulmonary disease 28 (17.9%) 2 (13.3%) 26 (18.4%) 0.89
Pulmonary hypertension 11 (7.1%) 1 (6.7%) 10 (7.1%) 1
Osteoporosis 6 (3.8%) 2 (13.3%) 4 (2.8%) 0.10
Peripheral artery disease 27 (17.3%) 4 (26.7%) 23 (16.3%) 0.52
NYHA class IV 10 (6.4%) 1 (6.7%) 9 (6.4%) 1
MR grade ≥ 3 20 (12.8%) 5 (33.3%) 15 (10.6%) 0.04
LVEF [%] 50.69 ± 14.11 49.80 ± 19.79 50.78 ± 13.46 0.85
Hemoglobin [g/dL] 12.17 ± 1.62 12.18 ± 1.01 12.17 ± 1.67 0.99
Platelets [×109/L] 201.22 ± 65.7 185.7 ± 54.3 202.88 ± 66.7 0.34
Mean pressure gradient [mm Hg] 49.10 ± 15.47 48.33 ± 16.71 49.18 ± 15.39 0.84
Procedural data
Non-transfemoral access 35 (22.4%) 5 (33.3%) 30 (21.3%) 0.46
Self-expandable prosthesis 98 (62.8%) 10 (66.7%) 88 (62.4%) 0.97
Procedure time [min] 207.5 ± 54.7 220.5 ± 59.1 206.12 ± 54.2 0.34
Fluoroscopy time [min] 31.8 ± 12.6 30.8 ± 12.5 31.9 ± 12.6 0.76
Prosthesis size:
23 mm 15 (9.6%) 1 (6.7%) 14 (9.9%)
26 mm 58 (37.2%) 4 (26.7%) 54 (38.3%)
29 mm 69 (44.2%) 5 (33.3%) 64 (45.4%)
31 mm 13 (8.3%) 4 (26.7%) 9 (6.4%)
Major vascular complication 10 (6.4%) 1 (6.7%) 9 (6.4%) 1
AR post-TAVI, grade ≥ 3 9 (5.8%) 3 (20.0%) 6 (4.3%) 0.04
Data are presented as mean ± standard deviation or number (percentage). A p value of < 0.05 is considered statistically significant; AR — 
aortic regurgitation; CABG — coronary artery by-pass grafting; GFR — glomerular filtration rate; LVEF — left ventricular ejection fraction;  
MR — mitral regurgitation; NYHA — New York Heart Association; PCI — percutaneous coronary intervention; TAVI — transcatheter aortic 
valve implantation; TIA — transient ischemic attack
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Figure 1. 30-day all-cause mortality across the entire 
cohort with the majority of events occurring during the 
first 2 days.
Figure 2. Discriminating ability of analyzed risk scores 
— comparison of receiver operating characteristics 
curves; AUC — area under the curve.
Classification accuracy of risk models
In terms of classification accuracy — ability to 
reliably discriminated between high vs. non-high 
risk patients at a predefined threshold — ACEF 
model performed best demonstrating biggest dif-
ference between observed mortality in high- vs. 
non-high-risk cohort (17.5% vs. 6.9%, p = 0.053). 
Detailed analysis of classification accuracy of all 
risk models is shown in Figure 4.
Discussion
Transcatheter aortic valve implantation is 
a rapidly emerging new standard of care among high 
and extreme risk patients with severe AS. However, 
optimal risk stratification in the decision-making 
process of patients’ qualification for TAVI procedure 
continuously poses a challenge [4]. Although widely 
criticized by both surgeons [11] and cardiologists 
[12, 13], conventional surgical risk algorithms are 
still frequently used. Logistic EuroSCORE remains 
part of version 2012 of guidelines, even though it 
has been known to inaccurately estimate mortality 
(mainly overestimate) since 2008 [14–18]. In the 
need for better accuracy, newer scales were recently 
developed [5–9]. However, most of the scales were 
not subsequently validated in different populations, 
other than originally created on.
To the best of our knowledge, this has been 
the first paper simultaneously evaluating differ-
ent (established vs. recently proposed, surgical 
vs. interventional) risk scores in a most inclusive 
fashion (7 models) in the Polish population of 
unselected TAVI patients. We found that none 
of the investigated scales proved even mediocre 
discrimination accuracy as c-statistic for any risk 
model did not exceed 0.6 threshold. Similarly, none 
of the models was accurately calibrated across 
the whole risk spectrum meaning that some were 
calibrated well only in high risk while others only 
in non-high risk group. Finally, all models failed in 
being able to accurately classify patients into high 
or non-high risk categories, however the simplest 
one (ACEF) was closest to reach statistical signifi-
cance. Furthermore, univariate analysis of base-
line and periprocedural characteristics identified 
3 factors that occurred significantly more often in 
patients with an endpoint: MR grade ≥ 3, GFR 
< 30 mL/min/1.73 m2 and AR post-TAVI grade 
≥ 3 — findings consistent with previously pub-
lished observations [19–23].
Until now, few data exist on the head-to-head 
performance of different risk models in TAVI 
patients. Most of available papers compare predic-
tive ability of logistic EuroSCORE and STS with 
recently developed EuroSCORE II, usually show-
ing better efficacy of more refined EuroSCORE II 
[13, 24, 25]. Only few studies take into cosidera-
tion other scores. In 2013, D’Ascenzo et al. [26] 
reported poor discriminating ability of ACEF, based 
upon data from > 950 TAVI patients. In another 
paper, the SURTAVI model was deemed to be as 
inefficient in terms of classification accuracy as es-
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tablished surgical risk models [27]. More recently, 
low discriminating ability of Ambler’s score was 
documented [28]. Due to overall poor efficacy in the 
prediction of mortality, newer, specifically designed 
for TAVI scales were and still are in demand. In 
the present study, for the first time the authors 
compared conventional and unconventional surgi-
cal models with recently proposed TAVI-tailored 
scales. Only very modest if not poor differentiating 
ability of any of the studied models, irrespective 
if specifically designed for TAVI or surgical, was 
observed. In our opinion, this may be explained by 
lack of potentially important clinical (e.g. anemia, 
hypoalbuminemia, liver dysfunction) and anatomi-
cal factors (e.g. porcelain aorta, calcium distribution 
on the native valve, delivery route morphology). 
It can be speculated that abovementioned clinical 
factors reflect poor general health status, which 
can affect early rehabilitation process. On the other 
hand, unfavorable anatomical conditions may repre-
sent unsurpassable barrier to successful prosthesis 
implantation even for an experienced operator with 
available device technology.
When considering a preferable feature of 
a given risk model, out of 3 main characteristics, 
namely: discriminating ability, calibration and clas-
sification accuracy, we stand on the position that 
the last one is the most clinically useful, as in the 
Figure 3. Calibration of risk scores — comparison of observed vs. predicted 30-day mortality in high- and 
non-high-risk groups.
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Figure 4. Classification accuracy of risk scores — comparison of observed 30-day mortality in high-risk vs. 
non-high-risk group.
referral for TAVI we have to reliably categorize 
patients into high or non-high risk groups. In this 
light, if we were to recommend one of the studied 
models, we would lean toward ACEF not only 
because of acceptable classification accuracy, but 
also due to its simplicity.
Limitations of the study
The main limitation of the present study is 
a small sample size and, therefore low number of 
events. This rendered Cox multivariate regression 
analysis impossible (according to the rule of thumb, 
that at least 10 outcomes are required for each 
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independent variable in a multivariate model) as 
well as precluded more detailed subgroup examina-
tion and forced dichotomous cohort division (high- 
vs. non-high-risk). Nevertheless, this analysis is 
based on one of the biggest TAVI populations in 
Poland. Additionally, information concerning frailty, 
necessary for SURTAVI categorization, was not 
available in some patients.
Conclusions
In conclusion, results of our study demon-
strate that none of the risk models is optimal in 
predicting 30-day mortality in unselected, real-life 
population with AS referred to TAVI. None of the 
investigated scales proved to be significantly ac-
curate in terms of discrimination, calibration and 
classification. These data support primary role of 
the heart team in decision process of selecting 
patients for TAVI.
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